IceCure Medical Ltd(ICCM)Earnings, Financials & Key Ratios
ICCM•NASDAQ
Price updated Jun 3, 2026
AboutIceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Show more
- Revenue$3M+2.7%
- EBITDA-$15M+3.7%
- Net Income-$15M+1.7%
- EPS (Diluted)-0.24+20.0%
- Gross Margin36.28%-17.7%
- EBITDA Margin-437.97%+6.2%
- Operating Margin-446.7%+6.3%
- Net Margin-445.61%+4.3%
- ROE-188.78%-17.5%
- ROIC-13557.49%-1066.1%
- Debt/Equity0.02-64.0%
ICCM Key Insights
IceCure Medical Ltd (ICCM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Profits declining 25.8% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Shares diluted 25.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ICCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ICCM Price & Volume
IceCure Medical Ltd (ICCM) stock price & volume — 10-year historical chart
Loading chart...
ICCM Growth Metrics
IceCure Medical Ltd (ICCM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years16.05%
5 Years-3.72%
3 Years3.08%
TTM8.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM17.74%
Return on Capital
10 Years-115.11%
5 Years-109.29%
3 Years-142.83%
Last Year-187.2%
ICCM Recent Earnings
IceCure Medical Ltd (ICCM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 12, 2026EPS
$0.06
Est $0.03
-100.0%
Revenue
$911,000
Est $1M
-32.2%
Q2 2026
Mar 17, 2026EPS
$0.06
Est $0.04
-50.0%
Revenue
$1M
Est $1M
+0.0%
Q4 2025
Nov 19, 2025EPS
$0.06
Est $0.05
-20.0%
Revenue
$850,000
Est $1M
-34.6%
Q3 2025
Aug 13, 2025EPS
$0.06
Est $0.06
+0.0%
Revenue
$525,000
Est $639,000
-17.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.06vs $0.03-100.0% | $911,000vs $1M-32.2% |
| Q2 2026 | Mar 17, 2026 | $0.06vs $0.04-50.0% | $1Mvs $1M+0.0% |
| Q4 2025 | Nov 19, 2025 | $0.06vs $0.05-20.0% | $850,000vs $1M-34.6% |
| Q3 2025 | Aug 13, 2025 | $0.06vs $0.06+0.0% | $525,000vs $639,000-17.8% |
Based on last 12 quarters of dataView full earnings history →
ICCM Peer Comparison
IceCure Medical Ltd (ICCM) competitors in Imaging, radiation, and oncology devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.84B | 16.15 | -13.24 | 8.28% | -25.66% | -50.82% | 0.85 | |
 XTNT | 64.53M | 0.46 | 15.34 | 14.21% | 1.5% | 3.68% | 0.56 | |
 ATEC | 1.16B | 7.68 | -8 | 24.95% | -21.07% | -443.09% | 17.21 | |
 HALO | 8.28B | 69.82 | 27.27 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ISRG | 144.66B | 407.29 | 51.75 | 20.51% | 28.15% | 16.89% | 0.02 | |
 BSX | 70.88B | 47.69 | 24.58 | 19.87% | 14.4% | 12.4% | 0.51 | |
 MDT | 100.08B | 77.95 | 21.59 | 3.62% | 13% | 9.49% | 0.59 | |
 ABT | 151.32B | 87.02 | 11.39 | 4.59% | 31.88% | 27.26% | 0.32 |
Compare ICCM vs Peers
IceCure Medical Ltd (ICCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ICCM Income Statement
IceCure Medical Ltd (ICCM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 689.38K | 1.07M | 1.66M | 4.08M | 4.14M | 3.08M | 3.23M | 3.29M | 3.38M | 3.56M |
Revenue Growth % | 10.21% | 55.49% | 54.64% | 146.41% | 1.31% | -25.45% | 4.67% | 1.92% | 2.67% | 8.92% |
Cost of Goods Sold | 514.44K | 623.17K | 1.08M | 1.43M | 1.94M | 1.64M | 1.93M | 1.84M | 2.15M | 2.26M |
COGS % of Revenue | 74.62% | 58.14% | 65.23% | 34.92% | 46.96% | 53.16% | 59.74% | 55.91% | 63.72% | - |
Gross Profit | 174.93K▲ 0% | 448.73K▲ 156.5% | 576.41K▲ 28.5% | 2.66M▲ 361.2% | 2.19M▼ 17.4% | 1.45M▼ 34.2% | 1.3M▼ 10.0% | 1.45M▲ 11.6% | 1.23M▼ 15.5% | 1.3M▲ 0% |
Gross Margin % | 25.38% | 41.86% | 34.77% | 65.08% | 53.04% | 46.84% | 40.26% | 44.09% | 36.28% | 36.55% |
Gross Profit Growth % | -21.02% | 156.51% | 28.45% | 361.19% | -17.43% | -34.17% | -10.03% | 11.62% | -15.51% | - |
Operating Expenses | 2.84M | 3.62M | 5.19M | 7.02M | 11.92M | 18.18M | 16.88M | 17.15M | 16.32M | 31.07M |
OpEx % of Revenue | 411.94% | 337.63% | 312.8% | 171.87% | 288.04% | 589.43% | 522.64% | 521.03% | 482.98% | - |
Selling, General & Admin | 1.34M | 1.68M | 2.34M | 2.87M | 6.04M | 9.06M | 8.6M | 10.05M | 8.89M | 9.01M |
SG&A % of Revenue | 194.62% | 156.55% | 141.03% | 70.28% | 146.01% | 293.71% | 266.43% | 305.41% | 263.01% | - |
Research & Development | 1.5M | 1.94M | 2.85M | 4.08M | 5.88M | 9.12M | 8.27M | 7.1M | 7.43M | 7.98M |
R&D % of Revenue | 217.32% | 181.08% | 171.78% | 99.86% | 142.03% | 295.72% | 256.21% | 215.62% | 219.98% | - |
Other Operating Expenses | 0 | 0 | 0 | 70.59K | 0 | 0 | 0 | 0 | 0 | 1000K |
Operating Income | -2.66M▲ 0% | -3.17M▼ 19.0% | -4.61M▼ 45.4% | -4.36M▲ 5.4% | -9.72M▼ 122.9% | -16.74M▼ 72.1% | -15.58M▲ 6.9% | -15.7M▼ 0.8% | -15.09M▲ 3.8% | -29.77M▲ 0% |
Operating Margin % | -386.56% | -295.76% | -278.03% | -106.78% | -234.99% | -542.59% | -482.38% | -476.94% | -446.7% | -835.01% |
Operating Income Growth % | 14.13% | -18.97% | -45.37% | 5.36% | -122.94% | -72.14% | 6.95% | -0.77% | 3.84% | - |
EBITDA | -2.63M | -3.14M | -4.45M | -4.3M | -9.6M | -16.49M | -15.25M | -15.36M | -14.8M | -29.49M |
EBITDA Margin % | -381.72% | -292.89% | -268.66% | -105.24% | -231.92% | -534.55% | -472.38% | -466.85% | -437.97% | -827.29% |
EBITDA Growth % | 13.71% | -19.31% | -41.85% | 3.47% | -123.26% | -71.83% | 7.51% | -0.73% | 3.68% | -91.92% |
D&A (Non-Cash Add-back) | 33.38K | 30.8K | 155.37K | 63K | 127K | 248K | 323K | 332K | 295K | 275K |
EBIT | -2.82M | -3.47M | -4.75M | -4.14M | -9.72M | -16.74M | -15.58M | -15.7M | -15.09M | -15.68M |
Net Interest Income | -59.22K | -72.59K | -201.57K | 373.33K | -171K | -239K | 924K | 378K | 0 | -29K |
Interest Income | 1.95K | 556 | -178.76K | 412K | 0 | 0 | 924K | 378K | 0 | 21K |
Interest Expense | 61.16K | 73.15K | 22.81K | 38.67K | 171K | 239K | 0 | 0 | 0 | 50K |
Other Income/Expense | -210.9K | -363.76K | -165.18K | 412K | -171K | -239K | 924K | 378K | 37K | 14.03M |
Pretax Income | -2.88M▲ 0% | -3.53M▼ 22.9% | -4.77M▼ 35.1% | -4.69M▲ 1.8% | -9.89M▼ 111.0% | -16.98M▼ 71.6% | -14.65M▲ 13.7% | -15.32M▼ 4.5% | -15.06M▲ 1.7% | -15.74M▲ 0% |
Pretax Margin % | -417.15% | -329.7% | -288% | -114.83% | -239.13% | -550.34% | -453.76% | -465.45% | -445.61% | -441.6% |
Income Tax | 0 | 0 | 0 | 86.77K | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | -1.85% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.88M▲ 0% | -3.53M▼ 22.9% | -4.76M▼ 34.7% | -4.78M▼ 0.4% | -10.07M▼ 110.7% | -17.22M▼ 71.0% | -14.65M▲ 14.9% | -15.32M▼ 4.5% | -15.06M▲ 1.7% | -15.74M▲ 0% |
Net Margin % | -417.15% | -329.7% | -287.18% | -116.96% | -243.26% | -558.09% | -453.76% | -465.45% | -445.61% | -441.6% |
Net Income Growth % | 12.06% | -22.89% | -34.7% | -0.35% | -110.71% | -71.04% | 14.9% | -4.55% | 1.7% | -2.92% |
Net Income (Continuing) | -2.88M | -3.53M | -4.77M | -3.73M | -9.89M | -16.98M | -14.65M | -15.32M | -15.06M | -15.74M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.46▲ 0% | -0.30▲ 34.8% | -0.35▼ 16.7% | -0.28▲ 20.0% | -0.35▼ 25.0% | -0.47▼ 34.3% | -0.32▲ 31.9% | -0.30▲ 6.3% | -0.24▲ 20.0% | -0.21▲ 0% |
EPS Growth % | 25.81% | 34.78% | -16.67% | 20% | -25% | -34.29% | 31.91% | 6.25% | 20% | 17.74% |
EPS (Basic) | -0.46 | -0.30 | -0.35 | -0.28 | -0.35 | -0.47 | -0.32 | -0.30 | -0.24 | - |
Diluted Shares Outstanding | 6.26M | 11.67M | 13.62M | 17.13M | 28.55M | 37.02M | 45.64M | 50.88M | 63.58M | 73.57M |
Basic Shares Outstanding | 6.26M | 11.67M | 13.62M | 17.13M | 28.55M | 37.02M | 45.64M | 50.88M | 63.58M | 73.57M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ICCM Balance Sheet
IceCure Medical Ltd (ICCM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.86M | 5.15M | 6.9M | 9.68M | 30.32M | 28.13M | 14.18M | 10.75M | 12.61M | 12.12M |
Cash & Short-Term Investments | 1.46M | 4.19M | 5.78M | 3.5M | 25.62M | 23.66M | 11.06M | 7.56M | 8.9M | 8.12M |
Cash Only | 1.46M | 4.19M | 5.78M | 3.5M | 25.62M | 23.66M | 10.53M | 7.56M | 8.9M | 8.12M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 529K | 0 | 0 | 0 |
Accounts Receivable | 2 | 250.38K | 2 | 165K | 771K | 366K | 103K | 221K | 331K | 274K |
Days Sales Outstanding | 0 | 85.26 | 0 | 14.74 | 68.01 | 43.3 | 11.64 | 24.51 | 35.75 | 51.63 |
Inventory | 300.38K | 653.18K | 717.34K | 1.14M | 1.96M | 2.86M | 2.27M | 1.99M | 2.63M | 2.65M |
Days Inventory Outstanding | 213.12 | 382.57 | 242.16 | 292.33 | 367.25 | 635.86 | 430.47 | 394.36 | 445.02 | 415.95 |
Other Current Assets | 62.44K | 1 | 104.54K | 266K | 0 | 296K | 11K | 188K | 1K | 1.09M |
Total Non-Current Assets | 74.81K | 101.43K | 417.58K | 658.36K | 1.96M | 2.06M | 2.23M | 1.82M | 1.28M | 1.18M |
Property, Plant & Equipment | 43.73K | 73.81K | 377.44K | 621.67K | 1.63M | 2.02M | 2.19M | 1.78M | 1.23M | 1.13M |
Fixed Asset Turnover | 15.76x | 14.52x | 4.39x | 6.57x | 2.54x | 1.52x | 1.47x | 1.85x | 2.74x | 2.71x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 20.27K | 0 | 0 | 0 | 0 | 0 | 51K | 103K |
Other Non-Current Assets | 31.07K | 27.61K | 19.88K | 36.7K | 333K | 34K | 34K | 46K | 0 | 0 |
Total Assets | 1.93M▲ 0% | 5.25M▲ 172.1% | 7.32M▲ 39.3% | 10.34M▲ 41.3% | 32.28M▲ 212.3% | 30.19M▼ 6.5% | 16.41M▼ 45.6% | 12.58M▼ 23.4% | 13.89M▲ 10.4% | 13.3M▲ 0% |
Asset Turnover | 0.36x | 0.20x | 0.23x | 0.40x | 0.13x | 0.10x | 0.20x | 0.26x | 0.24x | 0.27x |
Asset Growth % | -41.71% | 172.07% | 39.27% | 41.27% | 212.28% | -6.48% | -45.64% | -23.36% | 10.43% | -2.13% |
Total Current Liabilities | 1.57M | 1.17M | 3.63M | 3.91M | 4.02M | 4.34M | 3.87M | 5.51M | 4.82M | 4.8M |
Accounts Payable | 152.49K | 452.98K | 425.67K | 645K | 881K | 714K | 502K | 1.23M | 863K | 988K |
Days Payables Outstanding | 108.19 | 265.31 | 143.7 | 165.07 | 165.5 | 158.91 | 94.99 | 244.39 | 146.31 | 167.94 |
Short-Term Debt | 936.24K | 0 | 0 | 0 | 0 | 0 | 0 | 298K | 204K | 134K |
Deferred Revenue (Current) | -1.18M | 0 | 2M | 0 | 884K | 646K | 187K | 334K | 255K | 255K |
Other Current Liabilities | 292.9K | 520.15K | 2.66M | 3.05M | 472K | 601K | 677K | 468K | 843K | 787K |
Current Ratio | 1.18x | 4.42x | 1.90x | 2.48x | 7.54x | 6.49x | 3.66x | 1.95x | 2.61x | 2.61x |
Quick Ratio | 0.99x | 3.86x | 1.70x | 2.18x | 7.06x | 5.83x | 3.08x | 1.59x | 2.07x | 2.07x |
Cash Conversion Cycle | 104.93 | 202.52 | 98.46 | 142.01 | 269.76 | 520.25 | 347.13 | 174.48 | 334.47 | 299.64 |
Total Non-Current Liabilities | 621.19K | 720.62K | 1.06M | 1.85M | 1.3M | 430K | 376K | 161K | 13K | 5K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 110.6K | 118K | 685K | 430K | 376K | 161K | 13K | 101K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 346.83K | 815.9K | 618K | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2.19M | 1.89M | 4.69M | 5.75M | 5.32M | 4.77M | 4.25M | 5.67M | 4.84M | 4.81M |
Total Debt | 936.24K | 0 | 245.18K | 301.04K | 909K | 597K | 599K | 459K | 217K | 139K |
Net Debt | -521.06K | -4.19M | -5.53M | -3.2M | -24.71M | -23.06M | -9.93M | -7.11M | -8.68M | -7.98M |
Debt / Equity | - | - | 0.09x | 0.07x | 0.03x | 0.02x | 0.05x | 0.07x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.27x |
Interest Coverage | -46.07x | -47.44x | -208.26x | -107.10x | -56.87x | -70.04x | - | - | - | -313.68x |
Total Equity | -256.93K▲ 0% | 3.37M▲ 1410.4% | 2.63M▼ 22.0% | 4.58M▲ 74.5% | 26.96M▲ 488.2% | 25.42M▼ 5.7% | 12.16M▼ 52.2% | 6.9M▼ 43.3% | 9.05M▲ 31.2% | 8.49M▲ 0% |
Equity Growth % | -112.22% | 1410.37% | -22% | 74.51% | 488.21% | -5.7% | -52.16% | -43.26% | 31.15% | -7.53% |
Book Value per Share | -0.04 | 0.29 | 0.19 | 0.27 | 0.94 | 0.69 | 0.27 | 0.14 | 0.14 | 0.12 |
Total Shareholders' Equity | -256.93K | 3.37M | 2.63M | 4.58M | 26.96M | 25.42M | 12.16M | 6.9M | 9.05M | 8.49M |
Common Stock | 1.26M | 2.7M | 3.47M | 5.03M | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -39.78M | -40.24M | -48.54M | -56.97M | -58.43M | -75.41M | -90.06M | -105.38M | -120.44M | -124.71M |
Treasury Stock | -50.06K | -46.2K | -50.25K | -41K | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 2.3M | 2.68M | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ICCM Cash Flow Statement
IceCure Medical Ltd (ICCM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.62M | -3.06M | -1.74M | -3.69M | -12.61M | -14.29M | -12.52M | -12.56M | -14.57M | -14.57M |
Operating CF Margin % | -380.76% | -285.83% | -105.09% | -90.34% | -304.62% | -463.27% | -387.77% | -381.74% | -431.31% | - |
Operating CF Growth % | 16.17% | -16.72% | 43.14% | -111.83% | -241.6% | -13.38% | 12.39% | -0.34% | -16.01% | -40.8% |
Net Income | -2.88M | -3.53M | -4.77M | -3.73M | -9.89M | -16.98M | -14.65M | -15.32M | -15.06M | -15.74M |
Depreciation & Amortization | 33.38K | 30.8K | 155.37K | 63K | 127K | 248K | 323K | 332K | 295K | 275K |
Stock-Based Compensation | 115.38K | 209.76K | 363.58K | 229K | 316K | 1.86M | 1.31M | 869K | 0 | -125K |
Deferred Taxes | 76.82K | 7.43K | 2.6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 4.89K | 212.68K | -59.49K | -452K | 5K | 359K | -25K | 39K | 1.26M | 993.56K |
Working Capital Changes | 20.43K | 9.56K | 2.57M | 200K | -3.16M | 214K | 523K | 1.51M | -1.07M | -653.88K |
Change in Receivables | 0 | 0 | 98.15K | 44K | -362K | 378K | 471K | -118K | -110K | 14K |
Change in Inventory | 53.23K | -375.98K | -6.93K | -386K | -891K | -902K | 582K | 287K | -637K | -615.62K |
Change in Payables | 0 | 0 | 2.29M | 217K | 236K | -167K | -212K | 730K | -369K | 26.33K |
Cash from Investing | -8.63K | -64.26K | -102.23K | -4.67M | 3.79M | -891K | -713K | 446K | -36K | 145.32K |
Capital Expenditures | -8.63K | -64.26K | -102.23K | -223K | -533K | -891K | -480K | -71K | -36K | -81.77K |
CapEx % of Revenue | 1.25% | 5.99% | 6.17% | 5.46% | 12.88% | 28.88% | 14.87% | 2.16% | 1.07% | - |
Acquisitions | 0 | 0 | 0 | 0 | -4.5M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 4.33M | 0 | -233K | -12K | 0 | -5M |
Cash from Financing | 1.05M | 5.98M | 3.06M | 5.86M | 30.89M | 13.58M | 83K | 9.19M | 15.83M | 17.22M |
Debt Issued (Net) | 1.02M | -925.6K | -105.12K | -171.98K | 0 | 0 | 0 | 0 | 0 | 2.01M |
Equity Issued (Net) | 0 | 6.91M | 3.37M | 5.86M | 30.55M | 13.57M | 83K | 9.19M | 15.83M | 7.75M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 26.18K | -2.66K | -205.9K | 171.98K | 337K | 2K | 0 | 0 | 0 | 7.46M |
Net Change in Cash | -1.66M▲ 0% | 2.85M▲ 271.6% | 1.22M▼ 57.3% | -2.29M▼ 288.2% | 22.12M▲ 1065.7% | -1.96M▼ 108.9% | -13.13M▼ 569.0% | -2.97M▲ 77.4% | 1.33M▲ 144.9% | 2.08M▲ 0% |
Free Cash Flow | -2.63M▲ 0% | -3.13M▼ 18.8% | -1.84M▲ 41.0% | -3.91M▼ 112.2% | -13.14M▼ 235.8% | -15.18M▼ 15.6% | -13M▲ 14.4% | -12.63M▲ 2.8% | -14.61M▼ 15.6% | -15.34M▲ 0% |
FCF Margin % | -382.01% | -291.83% | -111.25% | -95.8% | -317.5% | -492.16% | -402.63% | -383.9% | -432.38% | -430.16% |
FCF Growth % | 16.51% | -18.78% | 41.04% | -112.18% | -235.75% | -15.57% | 14.37% | 2.82% | -15.64% | -11.13% |
FCF per Share | -0.42 | -0.27 | -0.14 | -0.23 | -0.46 | -0.41 | -0.28 | -0.25 | -0.23 | -0.23 |
FCF Conversion (FCF/Net Income) | 0.91x | 0.87x | 0.37x | 0.77x | 1.25x | 0.83x | 0.85x | 0.82x | 0.97x | 0.97x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ICCM Key Ratios
IceCure Medical Ltd (ICCM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -311.57% | -227.28% | -158.86% | -132.53% | -63.83% | -65.74% | -77.97% | -160.7% | -188.78% | -211.73% |
| Return on Invested Capital (ROIC) | - | - | - | -236.64% | -402% | -545.13% | -509.13% | -1162.67% | -13557.49% | -13557.49% |
| Gross Margin | 25.38% | 41.86% | 34.77% | 65.08% | 53.04% | 46.84% | 40.26% | 44.09% | 36.28% | 36.55% |
| Net Margin | -417.15% | -329.7% | -287.18% | -116.96% | -243.26% | -558.09% | -453.76% | -465.45% | -445.61% | -441.6% |
| Debt / Equity | - | - | 0.09x | 0.07x | 0.03x | 0.02x | 0.05x | 0.07x | 0.02x | 0.02x |
| Interest Coverage | -46.07x | -47.44x | -208.26x | -107.10x | -56.87x | -70.04x | - | - | - | -313.68x |
| FCF Conversion | 0.91x | 0.87x | 0.37x | 0.77x | 1.25x | 0.83x | 0.85x | 0.82x | 0.97x | 0.97x |
| Revenue Growth | 10.21% | 55.49% | 54.64% | 146.41% | 1.31% | -25.45% | 4.67% | 1.92% | 2.67% | 8.92% |
Related:ICCM Dividend History·ICCM Revenue History·ICCM Price History·ICCM P/E History·ICCM Financial Ratios·ICCM Institutional Holders
ICCM Frequently Asked Questions
IceCure Medical Ltd (ICCM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
IceCure Medical Ltd (ICCM) reported $3.6M in revenue for fiscal year 2025. This represents a 234% increase from $1.1M in 2014.
IceCure Medical Ltd (ICCM) grew revenue by 2.7% over the past year. Growth has been modest.
IceCure Medical Ltd (ICCM) reported a net loss of $15.7M for fiscal year 2025.
Dividend & Returns
IceCure Medical Ltd (ICCM) has a return on equity (ROE) of -188.8%. Negative ROE indicates the company is unprofitable.
IceCure Medical Ltd (ICCM) had negative free cash flow of $15.3M in fiscal year 2025, likely due to heavy capital investments.